Home › Calculator › GRFS Dividend Calculator 2026
GRFS Dividend DRIP Calculator 2026
2.48% YieldHealthcareGrifols, S.A. · NASDAQ
Price: $7.08 · Annual div: $0.18/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When GRFS pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your GRFS snowball 📈
$10,000 in GRFS → $241.9K in 10 years · $55.40/month
About Grifols, S.A. (GRFS) — Dividend Analysis 2026
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Compare GRFS with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full GRFS DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GRFS position with:
🌍 GRFS Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold GRFS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.48% | -0.32% | $248 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.11% | -0.69% | $211 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.98% | -0.82% | $198 / yr |
| 🇬🇧 UK ISA | 0% | 2.48% | -0.32% | $248 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.26% | -0.54% | $226 / yr |
| 🇨🇦 TFSA | 0% | 2.48% | -0.32% | $248 / yr |
| 🇨🇦 CA Taxable | 25% | 1.86% | -0.94% | $186 / yr |
| 🇦🇺 Super (pension) | 15% | 2.11% | -0.69% | $211 / yr |
| 🇦🇺 AU Taxable | 30% | 1.74% | -1.06% | $174 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.83% | -0.97% | $183 / yr |
| 🇫🇷 FR Taxable | 30% | 1.74% | -1.06% | $174 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 GRFS Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.18/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 GRFS Dividend Payment Schedule
GRFS pays quarterly — 4 times per year. Next ex-div: TBD.
📊 GRFS vs Healthcare Benchmarks
How GRFS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GRFS sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ GRFS Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where GRFS earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GRFS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Grifols, S.A. (GRFS) is currently trading at $7.08, 63% below its 52-week high. The current dividend yield is 2.48% based on an annual payout of $0.18 per share.
GRFS (Grifols, S.A.) — 2.48% Dividend Yield Analysis
Grifols, S.A. (GRFS) is a healthcare stock currently trading at $7.08 with a dividend yield of 2.48%. The company pays an annual dividend of $0.18 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, GRFS has grown its dividend at a compound annual rate of 9.4%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.